For efficient transfection of specific primary cells, e.g. human T cells, CD34 or rat neurons, in the 4D-NucleofectorTM X Unit (100 µL format).
Do you need a quote right away? Add this product to your shopping cart, go to your cart and click on “Generate Quote”. Your quote will be available straight away to view, save online, and download in PDF format.
Human Stellate Cell Growth Media
For use with cell product HUCLS and HUCLS1.
For HUCLS-200K and HUCLS-1M, please see MST-500BK, StGM Bullet KitTM
ProCHO® 5 protein free CHO medium, with HEPES and 0.1% Pluronic® F-68, without L-Glutamine, phenol red, hypoxanthine or thymidine, 1 L (NAO)
Maintenance medium for use in adipogenic differentiation of mesenchymal stem cells
Induction Medium for adipogenic differentiation of mesenchymal stem cells
-
Cryopreserved Human LeukopakA brief guide and introduction to Lonza Cryopreserved Leukopak
-
Custom Human Immune Cell Isolations Toss SheetA brief introduction to the services that Lonza CellBio Service can offer with regards to custom immune cell isolations.
-
Instructions - Cryopreserved Human Stellate CellsTechnical Instructions for culturing human stellate cells
-
Discover the Freshness of Frozen PBMCsAn Assessment of Cryopreservation Impact on T Cell Activation
-
Human CD34+ Cells Technical information and instructions for use
-
Cold Storage of Fresh Leukopak Maintains Cell Viability and FunctionalityLearn how advanced cold storage approaches enable optimal levels of product integrity, quality, stability and viability
-
Primary Blood and Immune Cells for ResearchPresentation (PDF) showcasing Lonza's portfolio and capabilities of primary blood and immune cells for research.
-
Cryopreservation of Peripheral Blood Mononuclear CellsDoes Not Alter Immune Cell Phenotype
-
The Cell and Gene Therapies Journey from Translation to CommercializationDownload our comprehensive eBook on how to accelerate cell and gene therapy development, from translation to GMP production and commercialization.
-
An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cellsA strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells.